What Past US Agency Actions Say About Complexity in Merger Remedies, With an Application to Generic Drug Divestitures
Posted by Social Science Research Network
What Past US Agency Actions Say About Complexity in Merger Remedies, With an Application to Generic Drug Divestitures
By Eric Emch & Arthur Zhou (Bates White Economic Consulting); Thomas D. Jeitschko (Michigan State University)
Abstract: We consider merger remedies of the US Department of Justice’s Antitrust Division and the US Federal Trade Commission between 2008 and 2017. Traditionally one distinguishes between structural and behavioral remedies—and structural remedies are generally considered to be more effective and easier to implement. Our analysis suggests that over time this distinction has become somewhat blurred and a better gradation of remedies may be tied to the complexity of the proposed remedy. Divestitures in the market for generic drugs, in particular, are particularly complex, even though the remedies are of a structural, and so their efficacy is hard to ascertain.
Featured News
EU Set to Fine Apple in First Major Enforcement of Digital Markets Act
Nov 5, 2024 by
CPI
Six Indicted in Federal Bid-Rigging Schemes Involving Government IT Contracts
Nov 5, 2024 by
CPI
Ireland Secures First €3 Billion Apple Tax Payment, Boosting Exchequer Funds
Nov 5, 2024 by
CPI
Italy’s Data Protection Authority Criticizes Intesa’s Handling of Customer Data
Nov 5, 2024 by
CPI
Italy Halts Sale of ITA Airways Stake to Lufthansa Amid Price Dispute
Nov 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Remedies Revisited
Oct 30, 2024 by
CPI
Fixing the Fix: Updating Policy on Merger Remedies
Oct 30, 2024 by
CPI
Methodology Matters: The 2017 FTC Remedies Study
Oct 30, 2024 by
CPI
U.S. v. AT&T: Five Lessons for Vertical Merger Enforcement
Oct 30, 2024 by
CPI
The Search for Antitrust Remedies in Tech Leads Beyond Antitrust
Oct 30, 2024 by
CPI